Operative Treatment Of Metatarsalgia: Triple Weil Osteotomy Or Distal Metatarsal Minimal Invasive Osteotomy (DMMO)?
Launched by MANUEL CUERVAS-MONS · Jul 21, 2016
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
INTRODUCTION
Metatarsalgia is a vague term defining a symptom instead of a specific condition. The aim of surgical treatment of metatarsalgia is to decrease the pressure under metatarsal head, shortening and / or raising the metatarsal, thus removing the overload and preserving the joint integrity. It has been somewhat controversial, with more than 25 different lesser metatarsal osteotomies described to date. The Weil osteotomy is the most widely used surgical treatment in open distal metatarsal surgery, a popularity based upon the simple technique, stable fixation, excellent union rates a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all consecutive adult patients with the diagnosis of mechanical metatarsalgia served in the Department of Orthopaedic Surgery and Traumatology of the investigative hospital, without non-operative treatment response after 6 months
- Exclusion Criteria:
- • traumatic metatarsalgia
- • secondary metatarsalgia (diabetes, rheumatoid arthritis, or general diseases)
- • equinus contracture
- • active infection
- • systematic disease (inflammatory, metabolic, neurologic or vascular) explaining symptoms, - metatarsophalangeal (MTPJ) dislocation higher than 5mm
- • inability to complete postoperative management
- • previous forefoot surgeries
About Manuel Cuervas Mons
Manuel Cuervas-Mons is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic approaches, he leads and oversees clinical trials that aim to evaluate the safety and efficacy of new treatments across various therapeutic areas. His expertise in trial design, regulatory compliance, and data analysis ensures that studies are conducted with the highest standards of quality and integrity. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, Manuel Cuervas-Mons plays a pivotal role in translating scientific discoveries into meaningful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials